Clinical Trial Update: The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating continuing gefitinib after progression in EGFR-mutated non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gefitinib (Gefitinib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN